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        Epstein-Barr virus (EBV) is the fi  rst human virus 
shown to be etiologically associated with cancer. 
Although EBV establishes a lifelong latent infec-
tion in   >  90% of the world  ’  s population without 
serious sequelae, a small fraction of latently in-
fected individuals will develop malignancies of 
lymphocytic and epithelial origin, such as Bur-
kitt  ’  s lymphoma, Hodgkin  ’  s lymphoma, extra-
nodal nasal natural killer/T cell lymphoma, 
nasopharyngeal carcinoma (NPC), and gastric 
cancer (  1, 2  ). Among nearly 100 viral genes ex-
pressed during productive replication, only 11 
are expressed in latently infected cells. In addi-
tion, EBV was recently found to encode   >  20 
microRNAs (miRNAs) (  3  –  5  ). 
  miRNAs are gene regulatory RNAs of     22 
nt in length, and they negatively regulate gene 
expression either by inducing mRNA degrada-
tion or, more commonly in mammalian cells, by 
repressing translation (  6  ). Cellular miRNAs are 
critically involved in various biological processes 
such as development, apoptosis, and proliferation 
(  6  ). EBV was the fi  rst human virus found to en-
code miRNAs (  3  ). The EBV miRNAs are orga-
nized in two clusters within the EBV genome: 
one in the intronic regions of the BART gene 
(miR-BART1 to miR-BART-20) and the other 
in the untranslated regions (UTRs) of the BHRF1 
gene (miR-BHRF1-1 to miR-BHRF1-3) ( 3  –  5  ). 
Conservation of nine EBV miRNAs with coun-
terparts in the rhesus lymphocryptovirus points 
to the biological importance of these viral 
miRNAs (  4  ). Interestingly, miR-BARTs were 
found to be expressed abundantly in latently in-
fected epithelial cells but at a signifi  cantly lower 
level in B cells (  4  ), implicating a role in epithelial 
carcinogenesis. In further support of this, miR-
BARTs were also found to be highly expressed 
in EBV-associated gastric carcinoma (EBV-GC) 
cell lines and tissues (  7  ), in which only a few viral 
genes are constitutively expressed. 
  The function of most EBV miRNAs is 
poorly understood. Because miR-BART2 tran-
script is antisense to that of BALF5 and thus 
perfectly complementary to its 3     UTR, miR-
BART2 could target BALF5 mRNA for deg-
radation, thereby silencing the expression of 
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  Epstein-Barr virus (EBV) is a herpesvirus associated with nasopharyngeal carcinoma (NPC), 
gastric carcinoma (GC), and other malignancies. EBV is the fi  rst human virus found to 
express microRNAs (miRNAs), the functions of which remain largely unknown. We report 
on the regulation of a cellular protein named p53 up-regulated modulator of apoptosis 
(PUMA) by an EBV miRNA known as miR-BART5, which is abundantly expressed in NPC and 
EBV-GC cells. Modulation of PUMA expression by miR-BART5 and anti  –  miR-BART5 
oligonucleotide was demonstrated in EBV-positive cells. In addition, PUMA was found to be 
signifi  cantly underexpressed in     60% of human NPC tissues. Although expression of miR-
BART5 rendered NPC and EBV-GC cells less sensitive to proapoptotic agents, apoptosis can 
be triggered by depleting miR-BART5 or inducing the expression of PUMA. Collectively, our 
fi  ndings suggest that EBV encodes an miRNA to facilitate the establishment of latent 
infection by promoting host cell survival. 
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Actually, out of nine potential cellular targets shortlisted, 
PUMA was the only one that was shown to be suppressed by 
miR-BART5 in the reporter assay (Table S1). 
  The predicted miR-BART5 target site in the 3     UTR of 
PUMA exhibited good complementarity to miR-BART5 and 
was highly conserved among human, chimp, rhesus monkey, 
and mouse (  Fig. 1 A  ).   Although a 7-nt stretch that perfectly 
matches the 5     seed region of miR-BART5 was found in the 
predicted site, there were multiple mismatches in the central 
region (  Fig. 1 A  , top). 
  Although there are four isoforms of PUMA (    ,     ,     , and 
    ), all isoforms conserve the same 3     UTR and only two iso-
forms (PUMA-     and PUMA-    ) have proapoptotic activity 
(  13  ). To validate the interaction of miR-BART5 with the 3     
BALF5 viral DNA polymerase to inhibit lytic replication (  3, 8  ). 
Another recent study implicated the involvement of miR-
BHRF1-2 in the cleavage of BHRF1 RNA in the cytoplasm (  9  ). 
In contrast, an inverse correlation between expression levels 
of miR-BHRF1-3 and CXCL-11, which is an interferon-
inducible T cell –  attracting chemokine, implicated an immuno-
modulatory function of the viral miRNA in lymphomas (  10  ). 
In addition, miR-BARTs were also found to regulate the 
expression of LMP1 viral oncoprotein (  11  ). Although EBV 
miRNAs are important regulators of viral gene expression, 
they may also target cellular transcripts to facilitate viral per-
sistence and oncogenesis. Indeed, potential cellular targets 
of EBV miRNAs predicted by in silico analysis include 
growth regulators, modulators of apoptosis, B cell  –  specifi  c che-
mokines and cytokines, transcriptional regulators, and signal 
transducers (  3  ). However, experimental evidence for the con-
trol of cellular gene expression by EBV miRNAs remains to 
be established. 
  In this study, we sought to shed light on the roles of miR-
BARTs in establishing latent infection and driving carcinogen-
esis in epithelial cells through identifi  cation and characterization 
of their cellular targets. By bioinformatic analysis and func-
tional screening, p53 up-regulated modulator of apoptosis 
(PUMA), also known as BBC3 (Bcl2 binding component 3), 
was found to be targeted by miR-BART5. PUMA is a pro-
apoptotic protein belonging to the   “  BH3-only  ”   group of the 
Bcl-2 family (  12  –  14  ). Although it is an immediate downstream 
target of p53, PUMA can also induce p53-independent apop-
tosis in response to a wide variety of stimuli (  12, 15  –  17  ). In this 
paper, we provide the fi  rst evidence for the suppression of 
PUMA expression by miR-BART5. Overexpression and loss-
of-function experiments were performed to characterize the 
function of miR-BART5. The expression of PUMA in hu-
man NPC tissues was also examined. In addition, the func-
tional implications of miR-BART5  –  mediated silencing of 
PUMA in the survival of EBV  +   NPC and GC cells were in-
vestigated. Our work reveals a new molecular mechanism 
through which EBV confers resistance to apoptosis in NPC 
cells by counteracting the proapoptotic function of p53/
PUMA with a viral miRNA. 
    RESULTS   
  Identifi  cation of PUMA as a cellular target of miR-BART5 
  We predicted cellular targets of all miR-BARTs using mi-
Randa (  18, 19  ) and RNAhybrid (  20  ) programs, which have 
previously been shown to be successful in target prediction 
(  21  ). The top candidates for each miR-BART (for a list of 
top candidates for miR-BART5 see Table S1, available at 
http://www.jem.org/cgi/content/full/jem.20072581/DC1) 
were validated with reporter assays. Synthetic target sites were 
inserted into 3     UTR of luciferase gene, and the infl  uence of 
miR-BART on luciferase expression was assessed. miR-
BART5 was chosen for further study because the most pro-
nounced gene-silencing eff  ect on a cellular target named 
PUMA was observed with this miRNA in the reporter assay. 
    Figure 1.         PUMA is a cellular target of miR-BART5.   (A) Target site of 
miR-BART5 in 3     UTR of PUMA. The top shows the sequences in the 3    
UTR of PUMA that base pair with miR-BART5. The bottom shows the con-
servation of the target site sequences in different species of vertebrates. 
Conservative nucleotides are boxed. (B) Functional characterization of 
miR-BART5 target site. pGL3-PUMA.UTR has target sites of miR-BART5 
inserted into the 3     UTR of luciferase gene. This reporter construct was 
cotransfected into HeLa cells with an expression vector for either miR-
BART4 or miR-BART5. Plasmids pGL3-BART5.UTR and pGL3-GAPDH 
served as positive and negative controls, respectively. These control plas-
mids are different from pGL3-PUMA.UTR only in the 3     UTR of luciferase 
gene. pGL3-BART5.UTR contains target sequences perfectly matched with 
miR-BART5, whereas pGL3-GAPDH.UTR harbors irrelevant GAPDH se-
quences. In pGL3-mutPUMA.UTR, the target sites of miR-BART5 in the 
PUMA 3     UTR were mutated as indicated in the top. The relative luciferase 
activity was obtained by normalizing the readings of the fi  refl  y luciferase 
(Fluc) activity from the pGL3 vector with those of the   Renilla reniformis  
luciferase activity from pRL-CMV. Results represent mean   ±   SD from 
three independent experiments. (C and D) Functionality of miR-BART5 
target site in PUMA 3     UTR. A single copy of the entire PUMA 3     UTR  se-
quence was inserted into the 3     UTR of luciferase gene to generate pGL3-
PUMA.FL.UTR. This reporter construct was cotransfected into HeLa cells 
with an expression vector for either miR-BART4 or miR-BART5, or with 
commercially available synthetic RNA oligonucleotides pre  –  miRNA-NC or 
pre  –  miR-BART5. Plasmid pGL3-PUMA.FL.rUTR, in which a reversed single 
copy of the PUMA 3     UTR sequence was inserted into the 3     UTR of lucif-
erase gene, served as a negative control. Error bars indicate SD (n = 3). 
*, P = 0.2819 (by Student’s   t   test); **, P = 0.0346; #, P = 0.0042. ^, P = 0.0069.     JEM VOL. 205, October 27, 2008 
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cells. Although no miR-BART5 was found in HK1 cells, the 
expression signal of miR-BART5 in HK1/EBV was visible 
after longer exposure of the blot (  Fig. 2 A  , lanes 1 and 2). 
  Because miR-BARTs were also shown to be abundant in 
EBV-GC cells (  7  ), the expression of miR-BART5 in AGS/
BX1 was examined. AGS/BX1 cell line was established 
through infection of AGS cells with recombinant EBV virus 
carrying a GFP gene (  26  ). We noted that miR-BART5 was 
expressed in AGS/BX1 but not in EBV-negative AGS cells 
(  Fig. 2 A  , lane 7 compared with lane 6). In contrast, miR-
BART5 was not expressed in B95-8 cells (  Fig. 2 B  , lane 9; 
and Fig. S1, lane 21, available at http://www.jem.org/cgi/
content/full/jem.20072581/DC1) carrying a laboratory strain 
of EBV with a deletion in the miR-BART5 region (  4  ). In 
addition, miR-BART5 was hardly found in other EBV-
infected Burkitt  ’  s lymphoma cell lines, Akata, Namalwa, and 
Raji (Fig. S1, lanes 18  –  20). Thus, miR-BART5 was prefer-
entially expressed in EBV-infected NPC and GC cells. 
  We next extended our analysis of miR-BART5 expression 
to primary NPC tumor tissues and xenografts that had been 
verifi  ed to be positive for EBV-encoded small RNA (EBER). 
miR-BART5 was abundantly expressed in all NPC tumor 
UTR of PUMA, luciferase reporter assays were performed. 
Four copies of a PUMA 3     UTR fragment containing the 
predicted miR-BART5 target site were cloned into the 3     
UTR of the fi  refl   y luciferase gene. The resulting plasmid 
termed pGL3-PUMA.UTR was cotransfected into HeLa cells 
with the miR-BART5 expression vector, in which the ex-
pression of miR-BART5 was driven by the strong H1 pro-
moter (  22  ). Signifi  cant reduction of luciferase activity induced 
by miR-BART5 indicated that the miR-BART5 target site in 
PUMA 3     UTR is functional (  Fig. 1 B  ). The specifi  city of 
miR-BART5  –  mediated silencing of PUMA was further sup-
ported by several controls in the experiment. First, miR-
BART4, another miRNA encoded by EBV, did not show any 
inhibitory eff  ect on PUMA 3     UTR  –  dependent expression of 
luciferase gene. Second, miR-BART5 did not inhibit lucifer-
ase gene expression under the control of GAPDH sequences in 
cells receiving the pGL3-GAPDH.UTR reporter construct. 
Third, miR-BART5 suppressed reporter gene expression to 
similar magnitudes in cells receiving the pGL3-PUMA.UTR 
plasmid and the pGL3-BART5.UTR vector having 3     UTR 
sequences perfectly complementary to miR-BART5. Finally, 
when the miR-BART5 target sequences in PUMA 3     UTR 
were point mutated to disrupt complementarity to the seed re-
gion of miR-BART5 (  Fig. 1 B  , top), the inhibition of lucifer-
ase expression by miR-BART5 was completely abolished. 
  A criticism of this experiment is that multiple copies of 
partial 3     UTR sequence of PUMA were used. To address 
this issue, we constructed a plasmid in which a single copy of 
the entire 3     UTR of PUMA controls the expression of lu-
ciferase reporter. When we repeated the reporter assay with 
this construct, luciferase activity was signifi  cantly decreased 
in cells expressing miR-BART5 (  Fig. 1 C  ). This eff  ect was 
specifi  c, as no such inhibition was observed when miR-
BART4 was expressed. Likewise, specifi  c suppression of lu-
ciferase activity under the control of a single copy of the 
entire 3     UTR of PUMA was only seen in cells transfected 
with pre  –  miR-BART5, a chemically synthesized precursor 
miRNA (  Fig. 1 D  ). All these results consistently indicated 
specifi  c targeting of PUMA 3     UTR by miR-BART5. 
  Expression of miR-BART5 in EBV-infected epithelial cells 
  For miR-BART5 to fulfi  ll a gene regulatory function, it has to 
be expressed in EBV-infected cells. Because miR-BARTs 
were thought to be expressed preferentially in EBV-infected 
epithelial cells (  4, 7  ), we tested miR-BART5 expression in 
C666-1, an NPC cell line that constitutively harbors EBV (  23  ). 
For comparison, we also examined HK1, another NPC cell line 
that does not carry EBV (  24  ). In addition, the HK1/EBV cell 
line, to which EBV was reintroduced by coculture with in-
fected Akata cells (  25  ), was also included. Consistent with pre-
vious reports (  4, 11  ), ample amount of miR-BART5 was 
found in C666-1 cells (  Fig. 2 A  , lane 3).   The expression level 
of miR-BART5 in C666-1 cells was comparable to that in 
HEK293 cells stably transfected with miR-BART5 expression 
vector (  Fig. 2 A  , lane 5). As a control, miR-BART3-5p, an-
other miRNA encoded by EBV, was also detected in C666-1 
    Figure 2.         Expression of miR-BART5 in EBV-infected epithelial 
cells   (A) Northern blot analysis of EBV miRNAs in NPC and EBV-GC 
cell lines. HK1, HK1/EBV, and C666-1 are NPC cell lines (lanes 1  –  3). AGS/
BX1 is an EBV-GC cell line (lane 6). Untransfected HEK293 cells (293; lane 4), 
HEK293 cells stably expressing miR-BART5 (293/pmiR-BART5; lane 5), 
and AGS cells (lane 7) were included as controls. Expression signal of miR-
BART5 in HK1/EBV cells was visible only after long exposure (inset). The 5S 
rRNA served as a loading control. Although lanes 1  –  5 in the middle were 
from the same exposure of one experiment, lanes 6 and 7 were from an-
other experiment. (B) Northern blot analysis of miR-BART5 in human NPC 
tissue samples. Three normal nasopharyngeal biopsies (NP01, NP02, and 
NP03; lanes 2  –  4) and nine NPC tumor samples (NPC01 to NPC09; lanes 
5  –  8 and 11  –  15) were analyzed. C666-1 and latency III B95-8 lymphoblas-
toid cells (lanes 1, 9, and 10) were included as positive and negative con-
trols, respectively. U6 small nuclear RNA served as a loading control.     2554 EPSTEIN-BARR VIRUS MICRORNA TARGETS PUMA   | Choy et al. 
  To verify the expression state of PUMA in human NPC, 
we determined the amounts of PUMA-     protein in 25 pairs 
of matched NPC and non-NPC samples. The NPC and non-
NPC samples were collected from the same patient diagnosed 
with undiff  erentiated carcinoma, which is the most common 
histology in this region and associated with EBV (  2  ). Consis-
tent with results shown in   Fig. 2 B   and with a previous study 
(  27  ), expression of viral markers EBER and BART in all NPC 
samples, as well as the absence of these markers in all non-
NPC samples, were verifi  ed by RT-PCR (not depicted). Be-
cause of limited amount of sample, Northern blot analysis of 
miR-BART5 expression in the same sample was not possible. 
Among the 25 pairs of samples, a drop of PUMA-     protein 
expression was detected in     60% of the NPC tissues com-
pared with their corresponding non-NPC tissues. Notably, 
PUMA-     expression was undetectable in many NPC sam-
ples. For example, in 12 representative pairs of NPC and non-
NPC samples randomly selected (  Fig. 3 B  ), PUMA-     was 
diminished in 7 NPC samples (samples QM1, QM7, QM8, 
QM9, QM10, QM11, and QM12), among which a complete 
loss of PUMA expression was seen in 5 samples (samples 
QM7, QM8, QM9, QM10, and QM12). Considered to-
gether with results shown in   Fig. 1   and   Fig. 2  , we inferred that 
the expression of miR-BART5 was associated with severe in-
hibition of PUMA in undiff  erentiated NPC tissues. 
  Modulation of endogenous PUMA expression by miR-BART5 
  The above results provided the fi  rst experimental evidence for 
the regulation of PUMA expression by miR-BART5 of EBV. 
To test this idea more directly, we introduced pre  –  miR-
BART5, the specifi  city of which had been verifi  ed in   Fig. 1 D  , 
into PUMA-expressing HeLa cells. When the miR-BART5 
precursor RNA was expressed in the cells, substantial reduc-
tion in PUMA-     protein expression was observed, but this re-
duction was not seen in cells transfected with negative control 
precursor RNA (pre  –  miRNA-NC;   Fig. 4 A  , lanes 1 and 2).   
Likewise, a decline in PUMA-     expression was also observed 
when pre  –  miR-BART5 was overexpressed in HK1 cells (  Fig. 
4 A  , lane 4 compared with lane 3). Because of diff  erence in 
transfection effi   ciency (unpublished data), the magnitude of 
PUMA protein reduction in HK1 cells was not as great as in 
HeLa cells. To investigate the infl  uence of miR-BART5 on 
the expression of PUMA mRNA, RT-PCR was performed 
with cells transfected with miR-BART5 expression vector. 
Although PUMA transcript was amply found in cells that 
expressed miR-BART3-5p, it was undetectable in miR-
BART5-expressing cells (  Fig. 4 B  ). Hence, regulation of 
PUMA protein expression by miR-BART5 was associated 
with decreased level of PUMA mRNA. This is consistent with 
the model in which mRNAs translationally repressed by miR-
NAs might be stored in the P-bodies and subsequently de-
graded (  28, 29  ). 
  Enforced expression of miR-BART5 in HeLa and HK1 
cells led to inhibition of PUMA expression (  Fig. 4, A and B  ). In 
contrast, miR-BART5 was abundantly expressed in C666-1 
and AGS/BX1 cells (  Fig. 2 A  ). If miR-BART5 is an inhibitor 
samples to a level comparable with or even higher than that 
in C666-1 cells (  Fig. 2 B  , lanes 5  –  8 and 11  –  15; and Fig. S1, 
lanes 10, 16, and 17). In addition, most of the xenografts 
originally derived from NPC tumor were also strongly posi-
tive for miR-BART5 (Fig. S1, lanes 4, 5, 7, 14, and 15). In 
sharp contrast, miR-BART was not found in normal naso-
pharyngeal tissues obtained from three diff  erent subjects (  Fig. 
2 B , lanes 2 –  4). Hence, miR-BART5 was abundantly expressed 
in EBV-infected NPC tumor samples. This is consistent with 
reported expression pattern of miR-BART miRNAs in NPC 
and non-NPC samples (  4, 11  ). 
  PUMA expression in NPC cells and tissues 
  As demonstrated in the previous section, abundant miR-
BART5 expression was observed in EBV-infected epithelial 
cells and tissues. If miR-BART5 functions to counteract 
PUMA, a signifi  cant decrease of PUMA expression should 
occur in EBV  +   NPC cells expressing miR-BART5. To ad-
dress this issue, we compared the expression levels of PUMA 
in HK1 and HK1/EBV cells. These two NPC cell lines were 
chosen because HK1/EBV was derived from HK1 and it 
represents the EBV  +   counterpart of HK1 (  24, 25  ). The ex-
pression of PUMA-     and PUMA-     in HK1/EBV cells was 
diminished 2  –  2.5-fold when compared with the level in HK1 
cells (  Fig. 3 A  ).   Consistent with this, specifi  c and statistically sig-
nifi  cant (P   <   0.0027 by Student  ’  s   t   test) inhibition of luciferase 
expression from plasmid pGL3-PUMA.UTR was observed in 
HK1/EBV cells but not in HK1 cells (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20072581/DC1). 
These results are in accordance with viral modulation of PUMA 
expression plausibly through miR-BART5. 
    Figure 3.         Endogenous PUMA protein expression in EBV  +   NPC cell 
line and human primary NPC tissue samples.   (A) Western blot analysis 
of PUMA-     and PUMA-     proteins  in  miR-BART5 – expressing  HK1/EBV 
cells versus EBV        HK1 cells. (B) Western blot analysis of PUMA-     protein 
expression in 12 pairs of primary NPC tissue samples and noncancerous 
nasopharyngeal tissue samples. N, noncancerous nasopharyngeal tissue; 
T, tumorous NPC tissue.     JEM VOL. 205, October 27, 2008 
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in NPC cells. The importance of PUMA in mediating apop-
tosis prompted us to explore whether miR-BART5 inhibi-
tion of PUMA in NPC cells confers resistance to apoptosis. 
We compared the sensitivity of C666-1 and NP69 cells to 
adriamycin, a DNA-damaging agent that induces apoptosis. 
NP69 is an EBV        nasopharyngeal epithelial cell line, which 
is commonly used as a non-NPC counterpart of C666-1 (  23, 
30, 31  ). In line with our fi  nding on the underexpression of 
PUMA in HK1/EBV cells (  Fig. 3 A  ), the basal level of 
PUMA-     protein in C666-1 cells was signifi  cantly lower than 
in NP69 cells (  Fig. 5 A  ).   In addition, treatment with adriamycin 
induced PUMA-     expression in NP69 cells, but no signifi  -
cant induction was seen in C666-1 cells. Consistent with this, 
a majority of poly (ADP-ribose) polymerase (PARP) protein 
was found to be cleaved in NP69 cells treated with 0.8   μ  g/ml 
or 1.2   μ  g/ml adriamycin, but the percentages of cleaved 
PARP were much smaller in C666-1 cells treated with the 
same concentrations of adriamycin (  Fig. 5 A  ). The cleavage 
of PARP by caspase 3 facilitates cellular disassembly and serves 
as a sensitive marker of apoptosis (  32  ). Thus, our results sug-
gested that C666-1 cells expressing less PUMA-     were more 
resistant to apoptosis. A similar observation was also made 
with AGS/BX1 and HK1/EBV cells, which were less prone 
of PUMA expression, it should prevent the accumulation 
of PUMA protein in both C666-1 and AGS/BX1 cells. In 
other words, compromising the function of endogenous 
miR-BART5 in C666-1 cells should induce derepression of 
PUMA expression. Indeed, elevation of PUMA-     and 
PUMA-     proteins was observed in C666-1 cells when miR-
BART5 was specifi  cally inhibited with an anti  –  miR-BART5 
oligonucleo  tide (  Fig. 4 C  ). Consistent with this, luciferase re-
porter assay driven by PUMA 3     UTR was also found to be 
increased in C666-1 cells transfected with anti  –  miR-BART5 
(Fig. S3, available at http://www.jem.org/cgi/content/
full/jem.20072581/DC1). Likewise, an increase in the steady-
state amount of PUMA-     protein was detected in AGS/BX1 
cells transfected with anti  –  miR-BART5 (  Fig. 4 D  ). These 
results corroborated the notion that the expression of PUMA 
was eff  ectively repressed by miR-BART5 in EBV  +   epi-
thelial cells. 
  miR-BART5 protects host cells from apoptosis 
  In the previous section, we presented several lines of evi-
dence to support the regulation of PUMA by miR-BART5 
    Figure 4.         Modulation of PUMA expression by miR-BART5.  
(A) Down-regulation of PUMA-     protein expression by pre  –  miR-BART5. 
Pre  –  miR-BART5 and pre  –  miRNA-NC were introduced into HeLa and HK1 
cells. Expression of PUMA-     and     -tubulin proteins was analyzed by 
Western blotting. Relative PUMA-     protein amounts are shown at the 
bottom. (B) Down-regulation of PUMA mRNA expression by miR-BART5. 
miR-BART3-5p or miR-BART5 expression vector was transfected into 
HEK293 cells. PUMA and GAPDH transcripts were analyzed by RT-PCR. 
(C and D) Up-regulation of PUMA expression by anti  –  miR-BART5 in 
C666-1 and AGS/BX1 cells. Anti  –  miR-BART5 oligonucleotide inhibitor 
was transfected into miR-BART5  –  expressing C666-1 cells. Endogenous 
PUMA-     and PUMA-     proteins were detected by Western blotting. 
An irrelevant anti-miRNA oligonucleotide (anti  –  miRNA-NC) was used 
as a negative control. Relative PUMA-     protein amounts are shown 
at the bottom.     
    Figure 5.         EBV confers resistance to apoptosis.   (A) Sensitivity of 
NP69 and C666-1 cells to adriamycin. EBV        NP69 and EBV  +   C666-1  cells 
were treated with indicated concentrations of adriamycin for 48 h. 
PUMA-    , PARP and     -tubulin proteins were analyzed by Western blot-
ting. Shown at the bottom are relative expression levels of PUMA-     and 
percentages of cleaved PARP. (B) Sensitivity of AGS, AGS/BX1, HK1, and 
HK1/EBV cells to adriamycin. Cells were treated with 1.5   μ  g/ml (AGS and 
AGS/BX1 cells) or 1.2   μ  g/ml (HK1 and EBV/HK1) adriamycin for 48 h. Black 
lines indicate that intervening lanes have been spliced out.     2556 EPSTEIN-BARR VIRUS MICRORNA TARGETS PUMA   | Choy et al. 
eff  ectively inhibited by anti  –  miR-BART5 oligonucleotide 
(  Fig. 4, C and D  ), we tested the infl  uence of this miR-
BART5 inhibitor on apoptosis of C666-1 and AGS/BX1 
cells. Notably, transfection of C666-1 cells with anti  –  miR-
BART5 oligonucleotide triggered apoptosis (  Fig. 7 A   and 
Fig. S5, available at http://www.jem.org/cgi/content/full/
jem.20072581/DC1).   Additionally, anti  –  miR-BART5 oligo-
nucleotide was able to enhance the proapoptotic eff  ect of eto-
poside mildly leading to an    10% increase of TUNEL-positive 
apoptotic cells (  Fig. 7 A  ). Plausibly, both anti  –  miR-BART5 
oligonucleotide and etoposide exert their proapoptotic eff  ects 
by inducing the expression of PUMA. 
  To verify that the eff  ect of anti  –  miR-BART5 is indeed 
mediated through PUMA, we made use of small interfering 
RNA against PUMA (siPUMA), a validated siRNA targeting 
PUMA transcripts. As a fi  rst step, the eff  ectiveness of siPUMA 
to apoptosis than their respective parental cells (  Fig. 5 B  , lane 
4 compared with lane 2 and lane 8 compared with lane 6). 
Thus, miR-BART5  –  expressing cells (C666-1, AGS/BX1 and 
HK1/EBV) are less susceptible to apoptosis-inducing drugs. 
  Interestingly, we found that the resistance to apoptosis oc-
curred only in C666-1 cells treated with low-dose adriamycin 
(  <  1.2   μ  g/ml). Apoptosis was induced when the concentration 
of adriamycin was increased to 1.5   μ  g/ml or higher. Likewise, 
C666-1 cells treated with 80   μ  M etoposide also underwent 
apoptosis (  Fig. 6  ).   The manifestation of apoptosis in treated 
C666-1 cells was indicated by PARP cleavage (  Fig. 6 A  ) and 
by terminal deoxynucleotidyl transferase  –  mediated dUTP-bi-
otin nick end labeling (TUNEL) assay, which measures DNA 
fragmentation (  Fig. 6 B   and Fig. S4, available at http://www
.jem.org/cgi/content/full/jem.20072581/DC1). To investi-
gate the underlying mechanism of apoptosis, we determined 
the expression profi  le of p53 and PUMA-    . Interestingly, both 
p53 and PUMA-     were induced signifi  cantly by high-dose 
adriamycin and etoposide (  Fig. 6 A  ). Collectively, our results 
are compatible with the notion that the steady-state amount 
of PUMA dictates cellular sensitivity to proapoptotic agents. 
According to this model, when PUMA expression in C666-1 
cells was eff  ectively blocked by miR-BART5, apoptosis was 
prevented (  Fig. 5  ). However, if the inhibitory eff  ect of miR-
BART5 was overcome by high-dose proapoptotic agents, 
apoptosis was triggered (  Fig. 6  ). 
  To further strengthen this model, we asked whether in-
hibition of miR-BART5 by another means would also in-
duce apoptosis. Because miR-BART5 can be specifi  cally and 
    Figure 6.         Induction of PUMA expression in C666-1 cells leads to 
apoptosis.   (A) Western blot analysis of PARP. C666-1 cells were treatment 
with either 1.5   μ  g/ml adriamycin or 80   μ  M etoposide for 48 h. Expression 
of p53, PUMA-    , PARP, and     -actin was examined by Western blotting. 
(B) TUNEL analysis of apoptotic cells. TUNEL assays were performed on 
adriamycin- or etoposide-treated C666-1 cells by using confocal micros-
copy. Representative images are shown in Fig. S4 (available at http://www
.jem.org/cgi/content/full/jem.20072581/DC1). 250 cells were scored, and 
the quantitative results represent mean   ±   SD from three independent 
experiments. *, P = 0.035 (by Student  ’  s   t   test); #, P = 0.011.     
    Figure 7.         Inhibition of miR-BART5 in C666-1 cells induces apop-
tosis.   (A) Induction of apoptosis. C666-1 cells were transfected with anti  –
  miR-BART5 or anti  –  miRNA-NC oligonucleotide inhibitor. Cells were 
treated with etoposide as in   Fig. 6   and TUNEL assay was performed. Rep-
resentative images are shown in Fig. S5 (available at http://www.jem.org/
cgi/content/full/jem.20072581/DC1). 250 cells were scored and the quan-
titative results represent mean   ±   SD from three independent experiments. 
*, P = 0.03 (by Student  ’  s   t   test); #, P = 0.05. (B) Suppression of PUMA 
expression by siRNA. C666-1 cells were transfected with 100 nM siGFP or 
siPUMA. Expression of PUMA-     was examined by Western blotting. 
(C) Inhibition of miR-BART5 activity by siPUMA. C666-1 cells were co-
transfected with anti  –  miR-BART5 and siPUMA. Apoptotic cells were ana-
lyzed as in A. Error bars indicate SD (n = 3).     JEM VOL. 205, October 27, 2008 
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encodes an antiapoptotic Bcl-2 homologue that enhances cell 
survival (  36  ), whereas several protein products derived from 
BART mRNAs can modulate Notch signaling and RACK1-
orchestrated activities (  37, 38  ). miR-BART5 was derived from 
an intron of BART transcript. Although our fi  ndings on miR-
BART5 reveal another level of complexity in the functions of 
BART transcripts during EBV infection, the PUMA-suppress-
ing and antiapoptotic properties of miR-BART5 are gener-
ally consistent with existing knowledge on BARTs and EBV 
miRNAs. Our demonstration of the antiapoptotic function 
of miR-BART5 from EBV provides the fi  rst example for viral 
modulation of apoptosis through an miRNA. Plausibly, diff  er-
ent viral miRNAs might target diff  erent cellular proapoptotic 
proteins to promote host cell survival. 
  Although PUMA has the ability to mediate p53-indepen-
dent apoptosis, it remains an immediate and important down-
stream target of p53 (  12  –  17  ). p53 and PUMA are master 
regulators of cellular growth and apoptosis. In view of the re-
cent fi  nding that miR-34s are direct transcriptional targets of 
p53, the link between p53 and miRNAs is closer than ex-
pected (  39  ). However, one missing piece in the p53-miRNA 
puzzle is the regulation of p53 and p53 targets by miRNAs. 
In this perspective, our fi  ndings on the modulation of PUMA 
expression by miR-BART5 add a new dimension to our 
knowledge of p53 and miRNA. It remains to be elucidated 
whether p53 and PUMA might be targeted by other viral and 
cellular miRNAs. 
  Notably, Kaposi  ’  s sarcoma  –  associated herpesvirus miR-
K12-11 is an orthologue of cellular miR-155 (  40, 41  ). In ad-
dition, miR-BART5 of EBV shares signifi  cant seed homology 
with cellular miR-18a and miR-18b (  42  ). Although cellular 
miRNAs that target PUMA have not been identifi  ed, we can-
not rule out the possibility that miR-BART5 and a cellular 
miRNA might target the same 3     UTR sequence of PUMA 
mRNA. Hence, additional experiments are required to clarify 
whether the anti  –  miR-BART5 oligonucleotide used in our 
study might also aff  ect unidentifi  ed cellular miRNAs that reg-
ulate PUMA expression. 
  The modulation of PUMA by miR-BART5 was not sur-
prising. In NPC, p53 is rarely mutated (  43  ) but commonly acti-
vated likely through LMP1 (  44  ). Thus, EBV has to develop 
counter measures against p53 activation of PUMA to persist 
within the host cell. As demonstrated in our study, EBV can ex-
press ample amount of miR-BART5 to down-regulate the ex-
pression of proapoptotic PUMA in NPC and GC cells latently 
infected by EBV. This might explain the particularly high ex-
pression of miR-BART5 in epithelial cancer cells when com-
pared with EBV-positive lymphoma cells. It is also noteworthy 
that the underexpression of PUMA was observed only in     60% 
of the BART  +   NPC tissue samples (  Fig. 3  ). This raises the pos-
sibility that PUMA expression might be governed by more than 
one mechanism during EBV infection and carcinogenesis. 
  Our work has derived one new mechanism for EBV 
modulation of apoptosis. Based on this mechanism, new 
strategies can be devised to develop diagnostic tools and ther-
apeutic agents. For example, the detection of miR-BART5 
was confi  rmed by Western blot analysis of PUMA-     (  Fig. 7 B  ). 
We then cotransfected both anti  –  miR-BART5 and siPUMA 
into C666-1 cells and assessed the impact on apoptosis. A 
partial but signifi  cant suppression of anti  –  miR-BART5  –
  dependent proapoptotic activity by siPUMA (  Fig. 7 C  ) pro-
vided further support to our model. 
  Additionally, transfection of AGS/BX1 cells with anti  –
  miR-BART5 also induced apoptosis, but to a lesser extent 
(Fig. S6, available at http://www.jem.org/cgi/content/full/
jem.20072581/DC1). This weaker eff  ect might be ascribed 
to a higher basal level of apoptosis in anti  –  miRNA-NC  –
  transfected AGS/BX1 cells, which had been selected with 
G418. Collectively, our results consistently demonstrated that 
miR-BART5 protects host epithelial cells from apoptosis. 
    DISCUSSION   
  In this study, we provided the validation of a cellular target of 
EBV miRNA and characterized the antiapoptotic function of 
an EBV miRNA. Three lines of evidence were presented to 
support the regulation of PUMA protein expression by miR-
BART5 in EBV-infected epithelial cells. First, an miR-
BART5 target site in the 3     UTR of PUMA transcript was 
identifi  ed and validated (  Fig. 1   and Fig. S2). Second, abundant 
expression of miR-BART5 in NPC cells (  Fig. 2   and Fig. S1) 
correlated with signifi   cant underexpression of PUMA in 
    60% of NPC tissues (  Fig. 3  ). Third, manipulation of miR-
BART5 expression in NPC cells and an miR-BART5 pro-
ducing carcinoma cells from another origin (EBV-GC cells) 
by overexpression and depletion with an oligonucleotide in-
hibitor resulted in repression and derepression of PUMA ex-
pression, respectively ( Fig. 4 ). More importantly, miR-BART5 
was shown to have antiapoptotic activity in both NPC and 
EBV-GC cells. Although EBV  +   NPC and EBV-GC cells 
were found to be less susceptible to apoptosis (  Fig. 5  ), induced 
expression of endogenous PUMA by either pharmaceutical 
agent or anti  –  miR-BART5 oligonucleotide triggered apop-
totic death of these cells (  Figs. 5  –  7   and S3  –  S5). Our fi  ndings 
suggest a new mechanism for the survival of EBV-infected 
epithelial cells in which miR-BART5 targets PUMA to con-
fer resistance to apoptosis. This work has important implica-
tions not only in EBV biology and pathogenesis, but also in 
the development of new anti-EBV and anticancer agents. 
  Herpesviruses encode various miRNAs to regulate viral 
replication and to counteract host defense such as apoptosis and 
immunity (  33  ). For example, CMV exploits miR-UL112-1 to 
evade immune surveillance by suppressing MICB gene (  34  ) 
and to inhibit expression of the major immediate-early genes 
(  35  ). In EBV,   >  20 viral miRNAs are categorized into two 
main groups, namely miR-BHRF1 and miR-BARTs (  3  –  5  ). 
Although some of the EBV miRNAs are thought to modulate 
viral gene expression by targeting BALF5 and LMP1 (  3, 11  ), 
miR-BHRF1-3 has been proposed to repress expression of a 
chemokine named CXCL-11, which attracts T cells in re-
sponse to interferons (  10  ). It is noteworthy that other viral 
genes in the BHRF1 and BART regions also have regulatory 
function in apoptosis and cell signaling. As such, BHRF1 gene 2558 EPSTEIN-BARR VIRUS MICRORNA TARGETS PUMA   | Choy et al. 
EMBL/DDBJ under accession no.   NM_014417  ) into the XbaI site of pGL3-
Control, which is located immediately after the stop codon of the luciferase 
gene (Promega). As controls, luciferase reporter plasmid pGL3-GAPDH.UTR 
contains four copies of irrelevant sequences derived from GAPDH, whereas 
pGL3-BART5.UTR carries four repeats of sequences perfectly complementary 
to miR-BART5. pGL3-mutPUMA.UTR was derived from pGL3-PUMA.
UTR, with the change of 4 nt introduced with QuikChange site-directed 
mutagenesis kit (Stratagene). As for reporter plasmid pGL3-PUMA.FL.UTR, 
a single copy of the entire 3     UTR of PUMA was cloned by PCR am-
plifi  cation of nt 878  –  1695 in PUMA gene (available at GenBank/EMBL/
DDBJ under accession no.   NM_014417  ) and then inserted into the XbaI site 
of pGL3-Control. In plasmid pGL3-PUMA.FL.rUTR, the reverse sequence of 
PUMA 3     UTR was inserted. PUMA cDNA was supplied by B. Vogelstein 
(Johns Hopkins University, Baltimore, MD) and K. Vousden (the Beatson 
Institute for Cancer Research, Glasgow, UK). 
  RNA analysis.     50   μ  g of total RNA extracted from cultured cells using 
Trizol reagent (Invitrogen) was subjected to Northern blotting as detailed 
elsewhere (  45  ). cDNA was also synthesized from Trizol-extracted RNA 
with ThermoScript reagents (Invitrogen). Semiquantitative PCR was per-
formed with 2   μ  l of the synthesized cDNA using the following thermal cy-
cling profi  le: 94  °  C for 5 min, 30 cycles of amplifi  cation (94  °  C for 1 min, 
55  °  C for 20 s, and 72  °  C for 45 s), and 72  °  C for 7 min. 
  Tumor samples.     For Northern blot analysis, NPC tumor biopsies volun-
tarily donated by 15 individuals were obtained from the Department of Ana-
tomical and Cellular Pathology at the Prince of Wales Hospital (Chinese 
University of Hong Kong). Human experiments were approved by Joint 
Clinical Research Ethics Committee of the Chinese University of Hong 
Kong and Hospital Authority New Territories East Cluster. 75% of the NPC 
patients were male, whereas two patients were males in the control group. 
The age of subjects ranged from 25 to 71 yr old. The NPC patients were di-
agnosed with primary NPC of stages 1  –  4 (  51  ), except for one patient who 
had local nasopharyngeal recurrent of NPC. For Western blot analysis,     30 
pairs of matched NPC and non-NPC samples of the same individual were 
obtained from Queen Mary Hospital (University of Hong Kong) with the 
consent of patients for tissue donation. Human experiments were approved 
by Institutional Review Board of the University of Hong Kong and Hospital 
Authority Hong Kong West Cluster. 65% of the patients were male. The age 
of patients ranged from 41 to 68 yr old. Biopsies were taken and endoscopic 
assessment of the nasopharynx was performed before the start of treatment. 
Matched samples were taken from the tumor and the grossly unaff  ected side 
of nasopharynx for study. All tumor specimens were histologically evaluated 
to be undiff  erentiated carcinoma, except for one patient who had poorly 
diff  erentiated squamous carcinoma. The patients were diagnosed to have 
primary NPC of stages 1  –  4 (  51  ). All samples were snap frozen in liquid ni-
trogen and stored at     80  °  C until lysed with RIPA for Western blot analysis. 
Generally consistent with previous fi  ndings (  27  ), all NPC samples tested for 
PUMA expression were positive for EBER and BART transcripts by RT-
PCR, whereas all non-NPC tissues were negative for EBER or BART. 
  Western blotting.     RIPA buff  er (50 mM Tris-Cl, pH 7.4, 150 mM NaCl, 
1% Triton X-100, 0.1% SDS, and 1% sodium deoxycholate) was used to lyse 
the cells for SDS-PAGE analysis (  45, 50  ). The primary antibodies included a 
rabbit monoclonal against PUMA (Abcam), a mouse monoclonal against p53 
(Santa Cruz Biotechnology, Inc.), a rabbit polyclonal against PARP (Cell Sig-
naling Technology), and a mouse monoclonal antibody against     -tubulin or 
    -actin (Sigma-Aldrich). The anti-PUMA antibody preferentially reacts with 
PUMA-    , but the PUMA-     isoform can also be detected in some cells. 
  Apoptosis assays.     PARP cleavage in apoptotic cells was monitored by 
Western blotting. TUNEL assay was performed by confocal microscopy 
with fl  uorescein-based reagents (in situ cell death detection kit; Roche). 
  Online supplemental material.     Fig. S1 shows the expression of miR-
BARt5 in EBV-infected cells and tissues. Fig. S2 presents the comparison 
could be useful in the diagnosis of NPC and EBV-GC. In 
addition, miR-BART5 is a potential therapeutic target in 
NPC, EBV-GC, and other EBV-associated epithelial malig-
nancies. The use of anti  –  miR-BART5 oligonucleotide in-
hibitor to specifi  cally induce apoptosis in epithelial cancer 
cells may prove useful in anti-EBV and anti-cancer therapy. 
  MATERIALS AND METHODS 
  Target prediction.     miRanda (  18  ) and RNAhybrid (  20  ) were used to pre-
dict the potential targets of EBV miRNAs. Human 3     UTR sequences were 
retrieved using BioMart (http://www.ensembl.org/Multi/martview) and 
subsequently fed into miRanda for prediction, with an energy threshold 
of     20 kcal/mol and a cutoff   score of 120 to increase the stringency. Po-
tential targets ranked within the top 50 (see Table S1 for a list of potential 
targets of miR-BART5 predicted by miRanda) were then reanalyzed using 
RNAhybrid. Cross species conservation was also assessed using University 
of California Santa Cruz Human BLAT (http://genome.ucsc.edu/cgi-bin/
hgBlat?command=start). Potential target sites with a minimum free energy 
of   <      30 kcal/mol, as predicted by RNAhybrid, were shortlisted for func-
tional screening with luciferase reporter assays. 
  For prediction of miR-BART5 targets, nine potential targets were ob-
tained after analysis by miRanda and RNAhybrid. Although PUMA was 
ranked 43rd in the list of targets predicted by miRanda, it was selected for 
validation by reporter assay because the target site was predicted to have a 
minimum free energy of     30.7 kcal/mol (Table S1). Among all potential 
target sites verifi  ed by reporter assay, PUMA was the only one that was sup-
pressed by miR-BART5 (Table S1). 
  Cell culture, transfection, and reporter assay.     HeLa and HEK293 cell 
lines; human NPC cell lines C666-1, HK1, and HK1/EBV; human EBV-
GC cell line AGS/BX1 and its parental line AGS (provided by H. Chen and 
B. Wong, University of Hong Kong, Pokfulam, Hong Kong); human naso-
pharyngeal cell lines NP69 and NP460; and EBV-infected Burkitt  ’  s lym-
phoma cell lines Akata, B95-8, Namalwa, and Raji were cultured and 
transfected as previously described (  25, 26, 30, 45  –  49  ). NP69 and NP460 are 
epithelial cell lines immortalized with SV40 T antigen and are commonly 
regarded as the non-NPC counterpart of C666-1 (  25, 30, 31  ). 
  Transfection of cells with 100 nM of pre-miR miRNA precursor (Am-
bion), 150 nM of anti-miR miRNA inhibitor (Ambion), or 100 nM siRNA 
against PUMA mRNA (siPUMA; Thermo Fisher Scientifi  c) was performed 
using Lipofectamine 2000 (Invitrogen). Pre-miR miRNA precursors are 
small chemically modifi   ed double-stranded RNA molecules designed to 
mimic endogenous mature miRNAs. Anti-miR miRNA inhibitors are 
chemically modifi  ed single-stranded nucleic acids designed to specifi  cally 
bind to and inhibit the activity of endogenous miRNAs. siPUMA is an 
siRNA that targets nt 715  –  733 of PUMA mRNA (GenBank NM_014417). 
Pre-miR, anti-miR, and siPUMA oligonucleotides are ready-to-use rea-
gents with validated activity and specifi  city. 
  Dual luciferase reporter assay was performed as previously described (  45, 
50  ) using Dual-Luciferase reporter assay system (Promega). The readouts of 
luciferase activity were taken in an LB 96V microplate luminometer (EG  &  G 
Berthold). 
  Plasmid construction.     miR-BART expression vectors (pmiR-BART) 
were made by inserting miR-BARTs into pSuper vector (provided by R. 
Agami, Netherlands Cancer Institute, Amsterdam, Netherlands) (  22  ). miR-
BARTs were PCR-amplifi  ed using genomic DNA of C666-1 cells as tem-
plate. Primers for amplifi  cation of miR-BART5 (nt 946  –  1196, available at 
GenBank/EMBL/DDBJ under accession no.   EF102892  ) were 5    -GGAAGA-
TCTATAGAGACACAAGGACTGCCAGCC-3     (forward) and 5    -CCC-
AAGCTTCAAAAAACAAGAGCACACACCCACTGTATC-3     (reverse). 
Firefl  y luciferase reporter plasmid pGL3-PUMA.UTR bearing four copies 
of the miR-BART5 target site found in 3     UTR of PUMA was con-
structed by inserting PUMA sequences (nt 1331  –  1460, available at GenBank/JEM VOL. 205, October 27, 2008 
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